Increased expression of protein tyrosine phosphatase nonreceptor type 22 alters early T‐cell receptor signaling and differentiation of CD4+ T cells in chronic heart failure

Abstract CD4 + T‐cell counts are increased and activated in patients with chronic heart failure (CHF), whereas regulatory T‐cell (Treg) expansion is inhibited, probably due to aberrant T‐cell receptor (TCR) signaling. TCR signaling is affected by protein tyrosine phosphatase nonreceptor type 22 (PTPN22) in autoimmune disorders, but whether PTPN22 influences TCR signaling in CHF remains unclear. This observational case–control study included 45 patients with CHF [18 patients with ischemic heart failure versus 27 patients with nonischemic heart failure (NIHF)] and 16 non‐CHF controls. We used flow cytometry to detect PTPN22 expression, tyrosine phosphorylation levels, zeta‐chain‐associated protein kinase, 70 kDa (ZAP‐70) inhibitory residue tyrosine 292 and 319 phosphorylation levels, and CD4 + T cell and Treg proportions. We conducted lentivirus‐mediated PTPN22 RNA silencing in isolated CD4 + T cells. PTPN22 expression increased in the CD4 + T cells of patients with CHF compared with that in controls. PTPN22 expression was positively correlated with left ventricular end‐diastolic diameter and type B natriuretic peptide but negatively correlated with left ventricular ejection fraction in the NIHF group. ZAP‐70 tyrosine 292 phosphorylation was decreased, which correlated positively with PTPN22 overexpression in patients with NIHF and promoted early TCR signaling. PTPN22 silencing induced Treg differentiation in CD4 + T cells from patients with CHF, which might account for the reduced frequency of peripheral Tregs in these patients. PTPN22 is a potent immunomodulator in CHF and might play an essential role in the development of CHF by promoting early TCR signaling and impairing Treg differentiation from CD4 + T cells.